T1	Fact 25 213	The activation of the compensatory mechanisms results in an increase in cardiac output, an increase in ventricular volume and an increase in wall thickness through ventricular remodelling.
A1	Source T1 Averred
T2	KT_cue 25 81	The activation of the compensatory mechanisms results in
R1	Cue Arg1:T2 Arg2:T1	
T3	Fact 214 339	Tissue perfusion is also maintained via an increase in arterial pressure through the activation of the neurohormonal systems.
A2	Source T3 Averred
T4	Source_cue 214 249	Tissue perfusion is also maintained
R2	Cue Arg1:T4 Arg2:T3	
T5	Analysis 341 454	The initial activation of the compensatory mechanisms are deemed beneficial in the early stages of heart failure.
A3	Source T5 Averred
T6	KT_cue 341 405	The initial activation of the compensatory mechanisms are deemed
R3	Cue Arg1:T6 Arg2:T5	
A4	Modality T5
T8	Fact 455 680	After pro-longed activation of the compensatory mechanisms the response in the heart ultimately results in a vicious cycle of reduced heart function (chronic heart failure) eventually leading to death (Bernardo et al., 2010).
A5	Source T8 Non-integral_information_led_citation
T9	KT_cue 514 561	the response in the heart ultimately results in
R5	Cue Arg1:T9 Arg2:T8	
T10	Source_cue 656 680	(Bernardo et al., 2010).
R6	Cue Arg1:T10 Arg2:T8	
A6	Certainty_Level T5 L3
T12	Fact 682 790	Treatment strategies have been developed based upon  the  understanding  of  these  compensatory mechanisms.
A7	Source T12 Averred
T13	KT_cue 682 722	Treatment strategies have been developed
R8	Cue Arg1:T13 Arg2:T12	
T14	Fact 791 937	Medical therapy includes diuresis, suppression of the overactive neurohormonal systems, and augmentation of contractility (Clinton and John 2012).
A8	Source T14 Non-integral_information_led_citation
T15	KT_cue 791 815	Medical therapy includes
R9	Cue Arg1:T15 Arg2:T14	
T16	Source_cue 913 937	(Clinton and John 2012).
R10	Cue Arg1:T16 Arg2:T14	
T17	Fact 938 1128	Surgical options include ventricular resynchronization therapy, surgical ventricular remodelling, ventricular assist device implantation and heart transplantation (Lloyd-Jones et al., 2002).
A9	Source T17 Non-integral_information_led_citation
T18	KT_cue 938 962	Surgical options include
R11	Cue Arg1:T18 Arg2:T17	
T19	Source_cue 1101 1128	(Lloyd-Jones et al., 2002).
R12	Cue Arg1:T19 Arg2:T17	
T20	Fact 1130 1384	Despite significant understanding of the underlying pathophysiological  mechanisms  and  various treatments, heart failure still results in significant morbidity and carries a 50% 5-year mortality rate (World Health Organization. Cardiovascular disease).
A10	Source T20 Other_citation
T21	KT_cue 1239 1269	heart failure still results in
R13	Cue Arg1:T21 Arg2:T20	
T22	Source_cue 1332 1382	(World Health Organization. Cardiovascular disease
R14	Cue Arg1:T22 Arg2:T20	
T27	Observation 1615 1742	These responses include the activation of the immune system which aims to resolve the threat and rescue the damaged myocardium.
A13	Source T27 Non-integral_information_led_citation
T28	KT_cue 1615 1638	These responses include
R18	Cue Arg1:T28 Arg2:T27	
T29	Observation 1743 1915	Another response is the development of hypertrophy which aims to increase cardiac contractility to maintain a normal physiological function to meet the demands of the body.
A14	Source T29 Non-integral_information_led_citation
T30	KT_cue 1743 1762	Another response is
R19	Cue Arg1:T30 Arg2:T29	
T31	Fact 1941 2172	Cardiac hypertrophy is the initial adaptive response to correct the deficit in  cardiac  output during heart failure or pressure overload, resulting in the enlargement of the heart, known as cardiac remodelling (Dorn et al., 2003).
A15	Source T31 Non-integral_information_led_citation
T32	KT_cue 1941 1963	Cardiac hypertrophy is
R20	Cue Arg1:T32 Arg2:T31	
T33	Source_cue 2152 2172	(Dorn et al., 2003).
R21	Cue Arg1:T33 Arg2:T31	
T34	Fact 2173 2379	Cardiac remodelling involves molecular, cellular and interstitial changes that manifest clinically and cause an alteration in the size, shape and the general functioning of the heart (Abraham et al., 1997).
A16	Source T34 Non-integral_information_led_citation
T35	KT_cue 2173 2201	Cardiac remodelling involves
R22	Cue Arg1:T35 Arg2:T34	
T36	Source_cue 2356 2379	(Abraham et al., 1997).
R23	Cue Arg1:T36 Arg2:T34	
T37	Fact 2382 2463	Initially cardiac remodelling is beneficial in enhancing the cardiac functioning,
A17	Source T37 Non-integral_information_led_citation
T38	KT_cue 2392 2414	cardiac remodelling is
R24	Cue Arg1:T38 Arg2:T37	
T39	Observation 2464 2595	pro-longed cardiac remodelling has been shown to contribute significantly to ventricular dysfunction (Braunwald and Bristow, 2000).
A18	Source T39 Non-integral_information_led_citation
T40	KT_cue 2464 2509	pro-longed cardiac remodelling has been shown
R25	Cue Arg1:T40 Arg2:T39	
T41	Source_cue 2565 2595	(Braunwald and Bristow, 2000).
R26	Cue Arg1:T41 Arg2:T39	
T42	Analysis 2596 2766	This is because cardiac remodelling eventually induces pressure overload, the activation of the inflammatory response and an increase in volume load (Algra et al., 1991).
A19	Source T42 Non-integral_information_led_citation
A20	Certainty_Level T42 L4
T43	KT_cue 2604 2611	because
R27	Cue Arg1:T43 Arg2:T42	
T44	CL_cue 2612 2650	cardiac remodelling eventually induces
R28	Cue Arg1:T44 Arg2:T42	
T45	Source_cue 2745 2766	(Algra et al., 1991).
R29	Cue Arg1:T45 Arg2:T42	
T46	Fact 2768 2904	Heart failure results in different pathologies of the heart depending on the individuals (patient) response to the heart disease/injury.
A21	Source T46 Averred
T47	KT_cue 2768 2792	Heart failure results in
R30	Cue Arg1:T47 Arg2:T46	
T48	Analysis 2905 3068	Most heart failure patients have demonstrated the same molecular, biochemical, and cellular events ultimately resulting in the change of the myocardium  structure.
A22	Source T48 Averred
A23	Modality T48
A24	Certainty_Level T48 L3
T49	KT_cue 2905 2909	Most
R31	Cue Arg1:T49 Arg2:T48	 	
T52	Modality_cue 2905 2909	Most
R32	Cue Arg1:T52 Arg2:T48	
T53	CL_cue 2905 2909	Most
R33	Cue Arg1:T53 Arg2:T48	
T54	Fact 3069 3163	Cardiac remodelling can be categorised into two types; cardiac atrophy or cardiac hypertrophy.
A25	Source T54 Averred
T56	Fact 3164 3218	Heart failure patients experience cardiac hypertrophy,
A26	Source T56 Averred
T57	KT_cue 3164 3197	Heart failure patients experience
R35	Cue Arg1:T57 Arg2:T56	
T58	Investigation 3219 3342	this type of hypertrophy will be inflicted on the animals used during this study to illustrate a hypertrophic animal model.
A27	Source T58 Self_other
T59	KT_cue 3219 3264	this type of hypertrophy will be inflicted on
R36	Cue Arg1:T59 Arg2:T58	
T60	Source_cue 3282 3299	during this study
R37	Cue Arg1:T60 Arg2:T58	
T61	Fact 3369 3496	Cardiac hypertrophy is characterised by growth and thickening  of  the cardiac  muscles,  more so in the left ventricular wall.
A28	Source T61 Averred
T62	KT_cue 3369 3408	Cardiac hypertrophy is characterised by
R38	Cue Arg1:T62 Arg2:T61	
T63	Fact 3497 3640	The aim of cardiac hypertrophy is to boost cardiac contractility  and workload ensuring adequate delivery of blood and oxygen to the periphery.
A29	Source T63 Averred
T64	KT_cue 3497 3504	The aim
R39	Cue Arg1:T64 Arg2:T63	
T66	Fact 3642 3750	Cardiac hypertrophy or cardiac growth can be classified as either physiological or pathological hypertrophy.
A31	Source T66 Averred
T67	KT_cue 3642 3700	Cardiac hypertrophy or cardiac growth can be classified as
R41	Cue Arg1:T67 Arg2:T66	
T68	Analysis 3751 3824	Cardiac hypertrophy may occur as a result of either physiological stress.
A32	Source T68 Averred
A33	Modality T68
A34	Certainty_Level T68 L1
T70	Modality_cue 3751 3780	Cardiac hypertrophy may occur
R43	Cue Arg1:T70 Arg2:T68	
T71	CL_cue 3751 3780	Cardiac hypertrophy may occur
R44	Cue Arg1:T71 Arg2:T68	
T72	Fact 3825 3962	For example excessive exercise, pregnancy, or as a result of pathological stress such as arterial hypertension or valvular heart disease.
A35	Source T72 Averred
T74	Analysis 3963 4072	The difference in the signalling pathways involved in these two types of hypertrophy remains largely unknown.
A36	Source T74 Averred
A37	Certainty_Level T74 L2
T75	KT_cue 3963 4071	The difference in the signalling pathways involved in these two types of hypertrophy remains largely unknown
R46	Cue Arg1:T75 Arg2:T74	
T76	CL_cue 4056 4063	largely
R47	Cue Arg1:T76 Arg2:T74	
T77	Investigation 4073 4208	This study will be targeting pathological hypertrophy in the animal models to help understand the pathways involved during hypertrophy.
A38	Source T77 Self_other
T78	KT_cue 4073 4101	This study will be targeting
R48	Cue Arg1:T78 Arg2:T77	
T79	Source_cue 4073 4083	This study
R49	Cue Arg1:T79 Arg2:T77	
T80	Investigation 4209 4324	The difference between physiological and pathological hypertrophy is shown in Figure 1.2 below.[Figure 1.2 removed]
A39	Source T80 Self_other
T83	Fact 4359 4555	Physiological cardiac hypertrophy is a beneficial adaptive response of the cardiovascular system, occurring during growth, pregnancy and in response to extensive exercise (Richey and Brown, 1998).
A41	Source T83 Non-integral_information_led_citation
T84	KT_cue 4359 4395	Physiological cardiac hypertrophy is
R52	Cue Arg1:T84 Arg2:T83	
T85	Source_cue 4530 4555	(Richey and Brown, 1998).
R53	Cue Arg1:T85 Arg2:T83	
T86	Fact 4556 4739	Physiological hypertrophy enables the heart to meet the increased demands of the body by increasing left ventricular chamber dimensions with a proportional increase in wall thickness.
A42	Source T86 Averred
T87	KT_cue 4556 4589	Physiological hypertrophy enables
R54	Cue Arg1:T87 Arg2:T86	
T88	Fact 4740 4893	Physiological cardiac hypertrophy is characterised by an increase in myocyte size without the development of fibrosis or apoptosis (Anversa et al., 1986)
A43	Source T88 Non-integral_information_led_citation
T89	KT_cue 4740 4793	Physiological cardiac hypertrophy is characterised by
R55	Cue Arg1:T89 Arg2:T88	
T90	Source_cue 4871 4893	(Anversa et al., 1986)
R56	Cue Arg1:T90 Arg2:T88	
T91	Analysis 4894 4974	and is not associated with the development of cardiac disease and heart failure.
A44	Source T91 Averred
A45	Certainty_Level T91 L2
A46	Neg_CL T91
T92	CL_cue 4898 4920	is not associated with
R57	Cue Arg1:T92 Arg2:T91	
T93	KT_cue 4898 4920	is not associated with
R58	Cue Arg1:T93 Arg2:T91	
T94	Fact 4976 5075	In the late 19th century, Henschen was the first to recognise exercise-induced cardiac enlargement.
A47	Source T94 Other_citation
T95	KT_cue 5002 5014	Henschen was
R59	Cue Arg1:T95 Arg2:T94	
T97	Observation 5076 5123	He found hypertrophy on both sides of the heart
A48	Source T97 Irregular_citation
A49	Citation_length T97 Extended
T108	Observation 5340 5645	Maron and Pelliccia (2006) have found no evidence in the healthy population, excluding persons with underlying cardiovascular disease or genetic disorders, showing that remodelling due to exercise training leads to long term cardiac disease progression, cardiovascular disability, or sudden cardiac death.
A56	Source T108 Integral_citation
T109	KT_cue 5340 5377	Maron and Pelliccia (2006) have found
R69	Cue Arg1:T109 Arg2:T108	
T96	Source_cue 5002 5010	Henschen
R60	Cue Arg1:T96 Arg2:T94	
T98	KT_cue 5076 5084	He found
T50	Source_cue 5340 5366	Maron and Pelliccia (2006)
R67	Cue Arg1:T50 Arg2:T108	
T51	Analysis 5646 5675	It is generally accepted that
A30	Certainty_Level T51 L2
A57	Verb_noun T51 Attitude
A58	Source T51 Averred
T106	KT_cue 5646 5670	It is generally accepted
T111	Verb_cue 5646 5675	It is generally accepted that
R71	Cue Arg1:T111 Arg2:T51	
R70	Cue Arg1:T106 Arg2:T51	
T112	Fact 5676 5748	physiological cardiac hypertrophy in response to exercise is protective,
A59	Source T112 Averred
T113	KT_cue 5676 5736	physiological cardiac hypertrophy in response to exercise is
R73	Cue Arg1:T113 Arg2:T112	
T114	Analysis 5749 5798	in some instances it improves cardiac functioning
A60	Source T114 Averred
A61	Certainty_Level T114 L1
T115	KT_cue 5752 5756	some
R74	Cue Arg1:T115 Arg2:T114	
T116	CL_cue 5752 5756	some
R75	Cue Arg1:T116 Arg2:T114	
T117	Fact 5799 5838	and does not progress to heart failure.
A62	Source T117 Averred
A63	Neg_CL T117
T118	KT_cue 5803 5820	does not progress
R76	Cue Arg1:T118 Arg2:T117	
T122	Fact 5973 6141	For example, the increase in left ventricular mass  in a  woman during pregnancy will return to pre-pregnancy levels 6-12 weeks after giving birth (Mabie et al., 1994).
A66	Source T122 Non-integral_information_led_citation
A67	Modality T122
T123	KT_cue 5986 6065	the increase in left ventricular mass  in a  woman during pregnancy will return
R79	Cue Arg1:T123 Arg2:T122	
T124	Modality_cue 5986 6065	the increase in left ventricular mass  in a  woman during pregnancy will return
R80	Cue Arg1:T124 Arg2:T122	
T125	Fact 6174 6383	Pathological cardiac hypertrophy develops in response to various causes such as valvular heart disease, myocardial infarction, cardiac arrhythmias, endocrine disorders and hypertension (Bernardo et al., 2010).
A68	Source T125 Non-integral_information_led_citation
T126	KT_cue 6174 6215	Pathological cardiac hypertrophy develops
R81	Cue Arg1:T126 Arg2:T125	
T127	Source_cue 6359 6383	(Bernardo et al., 2010).
R82	Cue Arg1:T127 Arg2:T125	
T128	Fact 6384 6570	Pathological cardiac hypertrophy begins as an adaptive response to increase cardiac load in order to normalise cardiac wall stresses and maintain cardiac functioning (Levy et al., 1990).
A69	Source T128 Non-integral_information_led_citation
T129	KT_cue 6384 6423	Pathological cardiac hypertrophy begins
R83	Cue Arg1:T129 Arg2:T128	
T130	Source_cue 6550 6570	(Levy et al., 1990).
R84	Cue Arg1:T130 Arg2:T128	
T131	Fact 6650 6804	The remodelling is characterised by an abnormal enlargement of the heart structure  and  shape  which eventually results in a decline in cardiac function.
A70	Source T131 Averred
T132	KT_cue 6650 6685	The remodelling is characterised by
R85	Cue Arg1:T132 Arg2:T131	
T133	Analysis 6805 6940	The enlargement of the heart is due to the disruption of cellular architecture and rearrangement of both cardiac and non-cardiac cells.
A71	Source T133 Averred
T134	CL_cue 6805 6836	The enlargement of the heart is
R86	Cue Arg1:T134 Arg2:T133	
T135	Fact 6941 7027	In addition to the cardiac remodelling it also results in various other abnormalities.
T136	KT_cue 6980 6998	it also results in
R87	Cue Arg1:T136 Arg2:T135	
A72	Source T135 Averred
T137	Fact 7028 7306	These abnormalities include a shift towards glycolytic metabolism,  disarrangement  of  the sarcomeres, alteration in the calcium handling, changes in contractility, systolic or diastolic dysfunction, and loss of myocytes with fibrotic replacement (Heineke and Molkentin, 2006).
A73	Source T137 Non-integral_information_led_citation
T138	KT_cue 7028 7055	These abnormalities include
R88	Cue Arg1:T138 Arg2:T137	
T139	Source_cue 7276 7306	(Heineke and Molkentin, 2006).
R89	Cue Arg1:T139 Arg2:T137	
T69	KT_cue 3751 3780	Cardiac hypertrophy may occur
R42	Cue Arg1:T69 Arg2:T68	
T73	KT_cue 3837 3856	excessive exercise,
R45	Cue Arg1:T73 Arg2:T72	
R61	Cue Arg1:T98 Arg2:T97	
T99	Fact 6572 6649	Pathological hypertrophy in an irreversible cardiac remodelling of the heart.
A79	Source T99 Averred
T149	KT_cue 6572 6599	Pathological hypertrophy in
R62	Cue Arg1:T149 Arg2:T99	
A80	Certainty_Level T133 L4
T150	KT_cue 6837 6843	due to
R96	Cue Arg1:T150 Arg2:T133	
T7	CL_cue 341 405	The initial activation of the compensatory mechanisms are deemed
R4	Cue Arg1:T7 Arg2:T5	
T11	Analysis 7307 7386	Bernardo et al., (2010) study supported the above statements demonstrating that
A74	Verb_noun T11 Certainty
A75	Source T11 Integral_citation
A76	Certainty_Level T11 L4
T26	KT_cue 7307 7381	Bernardo et al., (2010) study supported the above statements demonstrating
R7	Cue Arg1:T26 Arg2:T11	
T140	CL_cue 7307 7381	Bernardo et al., (2010) study supported the above statements demonstrating
R17	Cue Arg1:T140 Arg2:T11	
T141	Verb_cue 7307 7386	Bernardo et al., (2010) study supported the above statements demonstrating that
R90	Cue Arg1:T141 Arg2:T11	
T142	Observation 7387 7606	pathological cardiac hypertrophy resulted in the loss of the cardiomyocytes ability to divide  and also that the cardiac heart muscle mass increased predominantly by the size of myocytes, rather than number of myocytes.
A77	Source T142 Integral_citation
T143	KT_cue 7387 7431	pathological cardiac hypertrophy resulted in
R91	Cue Arg1:T143 Arg2:T142	
T100	Analysis 5124 5142	and concluded that
A50	Source T100 Irregular_citation
A51	Verb_noun T100 Certainty
A52	Citation_length T100 Extended
A53	Certainty_Level T100 L3
T101	KT_cue 5128 5137	concluded
R63	Cue Arg1:T101 Arg2:T100	
T102	CL_cue 5128 5137	concluded
R64	Cue Arg1:T102 Arg2:T100	
T103	Verb_cue 5128 5142	concluded that
R65	Cue Arg1:T103 Arg2:T100	
T144	Observation 5143 5200	there was an enlargement of the heart following exercise.
A81	Citation_length T144 Extended
A82	Source T144 Irregular_citation
T146	KT_cue 5143 5152	there was
R92	Cue Arg1:T146 Arg2:T144	
T23	Analysis 1386 1426	Various studies have shown evidence that
A11	Verb_noun T23 Certainty
A12	Source T23 Non-integral_information_led_citation
A83	Certainty_Level T23 L4
T24	Source_cue 1386 1401;1595 1614	Various studies (Oka et al., 2014).
R15	Cue Arg1:T24 Arg2:T23	
T25	KT_cue 1386 1412	Various studies have shown
R16	Cue Arg1:T25 Arg2:T23	
T151	CL_cue 1386 1421	Various studies have shown evidence
R93	Cue Arg1:T151 Arg2:T23	
T152	Verb_cue 1386 1426	Various studies have shown evidence that
R97	Cue Arg1:T152 Arg2:T23	
T81	KT_cue 4209 4304	The difference between physiological and pathological hypertrophy is shown in Figure 1.2 below.
R50	Cue Arg1:T81 Arg2:T80	
T82	CL_cue 5652 5661	generally
R51	Cue Arg1:T82 Arg2:T51	
T105	Observation 7607 7735	The increase in the size of the myocytes reduced contractility in the heart causing a significant decline in cardiac functioning
A40	Citation_length T105 Extended
A78	Source T105 Integral_citation
T110	KT_cue 7607 7655	The increase in the size of the myocytes reduced
R66	Cue Arg1:T110 Arg2:T105	
T145	Analysis 7736 7767	due to stiffening in the heart.
A84	Certainty_Level T145 L4
T147	KT_cue 7736 7742	due to
R72	Cue Arg1:T147 Arg2:T145	
T65	Observation 5201 5339	Fagard (2003) also found that the left ventricular muscle mass in highly trained athletes is 60% greater than in non-athletic individuals.
A54	Source T65 Integral_citation
T104	Source_cue 5201 5214	Fagard (2003)
R40	Cue Arg1:T104 Arg2:T65	
A55	Verb_noun T65 Certainty
A85	Certainty_Level T65 L4
T107	KT_cue 5201 5225	Fagard (2003) also found
R68	Cue Arg1:T107 Arg2:T65	
T148	Verb_cue 5201 5230	Fagard (2003) also found that
R94	Cue Arg1:T148 Arg2:T65	
A86	Citation_length T27 Extended
A87	Citation_length T29 Extended
T153	Observation 1427 1614	following heart failure or damage, the heart activates a variety of intracellular adaptive responses in attempt to maintain a normal cardiac contractility and function (Oka et al., 2014).
A88	Source T153 Non-integral_information_led_citation
T154	KT_cue 1462 1481	the heart activates
R95	Cue Arg1:T154 Arg2:T153	
A90	Modality T54
T55	KT_cue 3069 3107	Cardiac remodelling can be categorised
R34	Cue Arg1:T55 Arg2:T54	
T156	Modality_cue 3069 3107	Cardiac remodelling can be categorised
R99	Cue Arg1:T156 Arg2:T54	
T157	Modality_cue 3642 3697	Cardiac hypertrophy or cardiac growth can be classified
R100	Cue Arg1:T157 Arg2:T66	
T119	Fact 5840 5972	The most distinguishing feature of physiological cardiac hypertrophy is its  ability to reverse  once the cardiac stress is removed.
A64	Source T119 Averred
T120	KT_cue 5840 5911	The most distinguishing feature of physiological cardiac hypertrophy is
R77	Cue Arg1:T120 Arg2:T119	
T121	Source_cue 6120 6141	(Mabie et al., 1994).
R78	Cue Arg1:T121 Arg2:T122	
A65	Source T145 Integral_citation
A89	Citation_length T145 Extended
